Concerns Surrounding Senores Pharmaceuticals' (NSE:SENORES) Performance

The stock price didn't jump after Senores Pharmaceuticals Limited (NSE:SENORES) posted decent earnings last week. We think that investors might be worried about some concerning underlying factors.

Our free stock report includes 1 warning sign investors should be aware of before investing in Senores Pharmaceuticals. Read for free now.

A Closer Look At Senores Pharmaceuticals' Earnings

Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

Over the twelve months to March 2025, Senores Pharmaceuticals recorded an accrual ratio of 0.44. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. Over the last year it actually had negative free cash flow of ₹2.0b, in contrast to the aforementioned profit of ₹585.6m. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of ₹2.0b, this year, indicates high risk.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Senores Pharmaceuticals' Profit Performance

As we discussed above, we think Senores Pharmaceuticals' earnings were not supported by free cash flow, which might concern some investors. For this reason, we think that Senores Pharmaceuticals' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Senores Pharmaceuticals as a business, it's important to be aware of any risks it's facing. In terms of investment risks, we've identified 1 warning sign with Senores Pharmaceuticals, and understanding this should be part of your investment process.

Today we've zoomed in on a single data point to better understand the nature of Senores Pharmaceuticals' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.